AmoyDx schließt Rahmenkooperationsvereinbarung mit AstraZeneca für mehrere Programme zur begleitenden Diagnostik in China, der EU und Japan ab
April 18, 2022 11:45 ET
|
Amoy Diagnostics Co., Ltd.
SHANGHAI, China, April 18, 2022 (GLOBE NEWSWIRE) -- Amoy Diagnostics Co., Ltd (AmoyDx), ein in China ansässiges Unternehmen für innovative Molekulardiagnostik (SZSE: 300685), gibt heute den...
AmoyDx conclut un accord-cadre de collaboration avec AstraZeneca pour plusieurs programmes de diagnostics compagnons en Chine, dans l'UE et au Japon
April 18, 2022 11:45 ET
|
Amoy Diagnostics Co., Ltd.
SHANGHAI, Chine, 18 avr. 2022 (GLOBE NEWSWIRE) -- Amoy Diagnostics Co., Ltd (AmoyDx), une société de diagnostics moléculaires innovants basée en Chine (SZSE : 300685), annonce aujourd'hui la...
AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan
April 18, 2022 08:03 ET
|
Amoy Diagnostics Co., Ltd.
SHANGHAI, China, April 18, 2022 (GLOBE NEWSWIRE) -- Amoy Diagnostics Co., Ltd (AmoyDx), a China based innovative molecular diagnostics company (SZSE: 300685), today announces that it has entered...
Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel
February 23, 2022 13:00 ET
|
Amoy Diagnostics Co., Ltd.
TOKYO and XIAMEN, China, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that an...